JP7551066B2 - 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ - Google Patents

血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ Download PDF

Info

Publication number
JP7551066B2
JP7551066B2 JP2021548536A JP2021548536A JP7551066B2 JP 7551066 B2 JP7551066 B2 JP 7551066B2 JP 2021548536 A JP2021548536 A JP 2021548536A JP 2021548536 A JP2021548536 A JP 2021548536A JP 7551066 B2 JP7551066 B2 JP 7551066B2
Authority
JP
Japan
Prior art keywords
expression
patient
gene
signature
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021548536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513402A (ja
JP2022513402A5 (enExample
Inventor
ジャン ケニス デビッドソン
サラ チャーチ
セルジオ ルテラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NS Wind Down Co Inc
Original Assignee
Nanostring Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanostring Technologies Inc filed Critical Nanostring Technologies Inc
Publication of JP2022513402A publication Critical patent/JP2022513402A/ja
Publication of JP2022513402A5 publication Critical patent/JP2022513402A5/ja
Priority to JP2024139452A priority Critical patent/JP2024178163A/ja
Application granted granted Critical
Publication of JP7551066B2 publication Critical patent/JP7551066B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2021548536A 2018-10-30 2019-10-29 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ Active JP7551066B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024139452A JP2024178163A (ja) 2018-10-30 2024-08-21 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862752659P 2018-10-30 2018-10-30
US62/752,659 2018-10-30
US201862769078P 2018-11-19 2018-11-19
US62/769,078 2018-11-19
US201962878368P 2019-07-25 2019-07-25
US62/878,368 2019-07-25
PCT/US2019/058616 WO2020092404A1 (en) 2018-10-30 2019-10-29 Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024139452A Division JP2024178163A (ja) 2018-10-30 2024-08-21 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ

Publications (3)

Publication Number Publication Date
JP2022513402A JP2022513402A (ja) 2022-02-07
JP2022513402A5 JP2022513402A5 (enExample) 2022-10-26
JP7551066B2 true JP7551066B2 (ja) 2024-09-17

Family

ID=70464448

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548536A Active JP7551066B2 (ja) 2018-10-30 2019-10-29 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ
JP2024139452A Pending JP2024178163A (ja) 2018-10-30 2024-08-21 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024139452A Pending JP2024178163A (ja) 2018-10-30 2024-08-21 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ

Country Status (13)

Country Link
US (1) US20210395374A1 (enExample)
EP (1) EP3873606A4 (enExample)
JP (2) JP7551066B2 (enExample)
KR (1) KR102943465B1 (enExample)
CN (3) CN113286633A (enExample)
AU (1) AU2019371243A1 (enExample)
BR (1) BR112021008283A2 (enExample)
CA (1) CA3118081A1 (enExample)
IL (1) IL282827A (enExample)
MX (1) MX2021004868A (enExample)
SG (1) SG11202104367RA (enExample)
WO (1) WO2020092404A1 (enExample)
ZA (1) ZA202102775B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022025834A2 (pt) * 2020-06-18 2023-01-10 Macrogenics Inc Método para determinar se um paciente seria um respondedor adequado ao uso de uma molécula biespecífica cd123 x cd3 para tratar uma malignidade hematológica e método de tratamento de uma malignidade hematológica
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
TW202241469A (zh) * 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
WO2023092119A2 (en) * 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
EP4499683A1 (en) * 2022-03-29 2025-02-05 NGM Biopharmaceuticals, Inc. Ilt3 and cd3 binding agents and methods of use thereof
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞
KR20250134857A (ko) * 2024-03-05 2025-09-12 사회복지법인 삼성생명공익재단 비소세포폐암 환자의 면역 관문 억제제에 대한 반응성을 예측하는 방법, 장치, 및 컴퓨터프로그램
CN120866362B (zh) * 2025-07-15 2026-03-31 郑州大学第一附属医院 过表达ifitm2基因的car-t细胞、构建方法及其在免疫细胞疗法中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005333987A (ja) 2004-05-06 2005-12-08 Veridex Llc 悪性血液疾患の予後
JP2017504577A (ja) 2013-08-23 2017-02-09 マクロジェニクス，インコーポレーテッド Ｃｄ１２３及びｃｄ３に結合できる二重特異性１価ダイアボディ、並びにその使用
WO2017069288A1 (en) 2015-10-23 2017-04-27 Daiichi Sankyo Company, Limited Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
WO2017214092A1 (en) 2016-06-07 2017-12-14 Macrogenics, Inc. Combination therapy
WO2018015340A1 (en) 2016-07-18 2018-01-25 Sanofi Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
US20160272720A1 (en) * 2013-11-06 2016-09-22 Memorial Sloan-Kettering Cancer Center Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes
PL3119807T3 (pl) * 2014-03-19 2019-09-30 Cellectis Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005333987A (ja) 2004-05-06 2005-12-08 Veridex Llc 悪性血液疾患の予後
JP2017504577A (ja) 2013-08-23 2017-02-09 マクロジェニクス，インコーポレーテッド Ｃｄ１２３及びｃｄ３に結合できる二重特異性１価ダイアボディ、並びにその使用
WO2017069288A1 (en) 2015-10-23 2017-04-27 Daiichi Sankyo Company, Limited Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
WO2017214092A1 (en) 2016-06-07 2017-12-14 Macrogenics, Inc. Combination therapy
WO2018015340A1 (en) 2016-07-18 2018-01-25 Sanofi Bispecific antibody-like binding proteins specifically binding to cd3 and cd123

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Comeau et al.，APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release，AACR Annual Meeting，Abstract No. 1786，2018年04月，Retrieved from the Internet, <URL: http://aptevo.mhwebstaging.com/wp-content/uploads/2018/06/AACR_2018_-_APVO436__Poster_FINAL_APPROVED_VERSION_040318.pdf>

Also Published As

Publication number Publication date
CN113286633A (zh) 2021-08-20
JP2024178163A (ja) 2024-12-24
CN119236065A (zh) 2025-01-03
KR20210110567A (ko) 2021-09-08
MX2021004868A (es) 2021-09-08
WO2020092404A1 (en) 2020-05-07
SG11202104367RA (en) 2021-05-28
BR112021008283A2 (pt) 2021-09-14
KR102943465B1 (ko) 2026-03-25
IL282827A (en) 2021-06-30
US20210395374A1 (en) 2021-12-23
EP3873606A4 (en) 2022-10-26
JP2022513402A (ja) 2022-02-07
EP3873606A1 (en) 2021-09-08
ZA202102775B (en) 2022-03-30
WO2020092404A8 (en) 2021-05-20
CA3118081A1 (en) 2020-05-07
CN119280393A (zh) 2025-01-10
AU2019371243A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
JP7551066B2 (ja) 血液悪性腫瘍の治療のための二重特異性ｃｄ１２３×ｃｄ３ダイアボディ
AU2023201367B2 (en) Chimeric receptor T cell treatment using characteristics of the tumor microenvironment
US20090087404A1 (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Besla et al. T cell–dependent bispecific therapy enhances innate immune activation and antibody-mediated killing
RU2837616C2 (ru) БИСПЕЦИФИЧНЫЕ ДИАТЕЛА CD123 х CD3 ДЛЯ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКИХ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
US20230220087A1 (en) Use of Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies
HK40095144A (zh) 双特异性cd123 x cd3双抗体用於治疗血液系统恶性肿瘤的用途
WO2026015853A1 (en) Enhancing activity and persistence of car-nk cells for the treatment of cancer and autoimmune diseases
HK40123134A (zh) 使用肿瘤微环境的特徵的嵌合受体t细胞治疗
HK40011995A (en) Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
HK40044133A (en) Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
HK1167337A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240821

R150 Certificate of patent or registration of utility model

Ref document number: 7551066

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150